C Paul
Overview
Explore the profile of C Paul including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
590
Citations
6572
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
King B, Mirmirani P, Lo Sicco K, Ramot Y, Sinclair R, Asfour L, et al.
J Eur Acad Dermatol Venereol
. 2025 Feb;
PMID: 39962358
Background: Ritlecitinib, an oral JAK3/TEC family kinase inhibitor, demonstrated efficacy over 48 weeks in patients with alopecia areata (AA) in the ALLEGRO phase 2b/3 study. Objectives: This post hoc analysis...
2.
Wild B, Wurmbach V, Boehlen F, Kusch M, Paul C, Friederich H, et al.
Aging Ment Health
. 2025 Feb;
:1-7.
PMID: 39960826
Objectives: The aim of the PACT (Prioritization by pArticipation) study was to evaluate the 'Life and Vitality Assessment' (LAVA) in terms of visualizing and exploiting priorities, resources, and problem areas...
3.
Pinter A, Costanzo A, Khattri S, Smith S, Carrascosa J, Tada Y, et al.
Dermatol Ther (Heidelb)
. 2024 May;
14(6):1495-1496.
PMID: 38814435
No abstract available.
4.
Tran C, Mahe E, Beylot-Barry M, Jullien D, Richard M, Fougerousse A, et al.
Ann Dermatol Venereol
. 2024 Mar;
151(2):103254.
PMID: 38554588
Background: French guidelines recommend stopping biologic treatment of psoriasis between 3 and 24 weeks before conception in accordance with the relevant Summary of Product Characteristics (SmPC). The aim of this...
5.
Pinter A, Costanzo A, Khattri S, Smith S, Carrascosa J, Tada Y, et al.
Dermatol Ther (Heidelb)
. 2023 Dec;
14(6):1479-1493.
PMID: 38113010
Introduction: Given the chronic nature of psoriasis (PsO), more studies are needed that directly compare the effectiveness of different biologics over long observation periods. This study compares the effectiveness and...
6.
Guedon C, Tauber M, Linder C, Paul C, Shourick J
Ann Dermatol Venereol
. 2023 Aug;
150(3):215-216.
PMID: 37598014
No abstract available.
7.
Nasseh J, Brun A, Theret V, Ramspacher J, Severino-Freire M, Coustou D, et al.
J Eur Acad Dermatol Venereol
. 2023 Aug;
38(1):e96-e98.
PMID: 37595985
No abstract available.
8.
Schakel K, Reich K, Asadullah K, Pinter A, Jullien D, Weisenseel P, et al.
J Eur Acad Dermatol Venereol
. 2023 Jun;
37(10):2016-2027.
PMID: 37262309
Background: Guselkumab is an interleukin (IL)-23 inhibitor with demonstrated efficacy in patients with psoriasis. Objectives: Evaluate the impact of early disease intervention on clinical responses following 28 weeks of guselkumab...
9.
Arlegui H, Mahe E, Richard M, De Rycke Y, Viguier M, Beylot-Barry M, et al.
Ann Dermatol Venereol
. 2023 Mar;
150(2):101-108.
PMID: 36914553
Background: The nature of the COVID-19 pandemic led to concerns among patients and physicians about the potential impact of immunosuppressive treatments for chronic diseases such as psoriasis on the risk...
10.
Curmin R, Guillo S, De Rycke Y, Bachelez H, Beylot-Barry M, Beneton N, et al.
J Eur Acad Dermatol Venereol
. 2022 Jul;
36(11):2101-2112.
PMID: 35793473
Background: Biologics are the cornerstone of treatment of patients with moderate-to-severe plaque psoriasis and switches between biologics are frequently needed to maintain clinical improvement over time. Objectives: The main purpose...